Document is current

Article History

Received: 3 February 2025

Accepted: 17 April 2025

First Online: 14 May 2025

Declarations

:

: Female 5–7-week-old BALB/c mice were obtained from the Experimental Animal Center of Hangzhou Medical College and Zhejiang Vital River Laboratory Animal Technology (Zhejiang, China). The mice were housed in barrier facilities under specific pathogen-free conditions and maintained under a 12-h light/dark cycle, with unrestricted access to food and water. The animal study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Hangzhou Medical College under the project titled, “Research on Novel Diagnostic and Therapeutic Techniques for Dermatological, Venereological, and Rheumatological Immune Diseases- Development of Umbilical Cord Mesenchymal Stem Cell-Based Therapy for Atopic Dermatitis” (Approval No: 2024–033; Date of Approval: April 11, 2024). The animal study has been reported according to ARRIVE 2.0 guidelines. The hUC-MSCs used in this study were provided for research purposes by S-Evans Biosciences. The supplier confirmed that original umbilical cord tissue collection was conducted following the protocol, “Collection, Preparation, and Preservation of Umbilical Cord and Placental Stem Cells,” approved by the Ethics Committee for Human Research at the Second Affiliated Hospital of Zhejiang University School of Medicine (Approval No. 2021–1135; Date of Approval: December 24, 2021); in addition, they confirmed that informed consent was obtained from all donors prior to tissue collection. As this study was conducted on pre-collected, anonymized cells, and did not involve direct human participation, no additional ethics approval was required for their use.

: Not applicable.

: The authors declare that they have no competing interests.